Clinical Trial Update: Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of different oral doses of BAY94-8862 in subjects with type 2 diabetes and diabetic nephropathy; study completed wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathies

Drugs mentioned

• BAY94-8862

Snippet

Sponsor: Bayer | Conditions: Diabetic Nephropathies | Phase 2 | Status: COMPLETED | Results posted: 2021-05-04